Compare SNFCA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | RNA |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.2M | 222.5M |
| IPO Year | 1995 | 2025 |
| Metric | SNFCA | RNA |
|---|---|---|
| Price | $8.79 | $10.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $69.26 |
| AVG Volume (30 Days) | 24.7K | ★ 238.7K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.51 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $344,587,538.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | $14.48 | ★ N/A |
| Revenue Growth | ★ 3.01 | N/A |
| 52 Week Low | $7.70 | $10.34 |
| 52 Week High | $10.23 | $73.06 |
| Indicator | SNFCA | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 30.76 |
| Support Level | $8.53 | N/A |
| Resistance Level | $9.40 | $14.30 |
| Average True Range (ATR) | 0.21 | 0.76 |
| MACD | 0.02 | -0.40 |
| Stochastic Oscillator | 11.49 | 2.06 |
Security National Financial Corp is a holding company providing insurance services. The company operates in three reportable business segments: Life insurance, Cemetery and Mortuary, and Mortgages. The life insurance segment sells and services selected lines of life insurance, annuity products, and accident and health insurance. The cemetery and mortuary segment engages in pre-need selling of funeral, cemetery, mortuary, and cremation services through its cemetery and mortuary locations. The mortgage segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and other real estate projects. It derives the majority of revenue from Life Insurance segment.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.